Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Triple Negative Breast Neoplasms × pyrotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 54 HER2-positive Breast Cancer 15 Carcinoma, Non-Small-Cell Lung 6 Brain Neoplasms 4 HER2 Positive Metastatic Breast Cancer 3 HER2 Positive Breast Cancer 3 Breast Diseases 3 Advanced Breast Cancer 3 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Early or Locally Advanced Breast Cancer 1

Interventions

pembrolizumab 132 Carboplatin 117 Paclitaxel 99 Cyclophosphamide 75 Capecitabine 54 130-nm albumin-bound paclitaxel 54 Doxorubicin 43 Gemcitabine 41 atezolizumab 34 Albumin-Bound Paclitaxel 33 Taxes 32 Cisplatin 32 Nivolumab 29 Docetaxel 28 sacituzumab govitecan 27 Epirubicin 26 Specimen Handling 24 Bevacizumab 24 olaparib 23 eribulin 23 durvalumab 22 Magnetic Resonance Spectroscopy 21 Drug Therapy 21 Biopsy 21 camrelizumab 19 toripalimab 17 Everolimus 13 veliparib 12 spartalizumab 12 liposomal doxorubicin 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03805399 2022-08-10

FUTURE

Fudan University

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡